NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04354727 2022-07-12A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyAscentage Pharma Group Inc.Phase 1/2 Withdrawn
NCT01787552 2020-04-15A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFNovartisPhase 1/2 Completed50 enrolled 23 charts
NCT00509899 2018-03-12Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisIncyte CorporationPhase 1/2 Completed154 enrolled 26 charts